Czech Multicentre Research Database of Chronic Obstructive Pulmonary Disease (COPD)
Czech Multicentre Research Database of Chronic Obstructive Pulmonary Disease (COPD)
The chronic obstructive pulmonary disease (COPD) is the occurrence of chronic bronchitis or
 emphysema, a pair of commonly co-existing diseases of the lungs in which the airways narrow
 over time. This limits airflow to and from the lungs, causing shortness of breath (dyspnoea).
 In clinical practice, COPD is defined by its characteristic airflow limitation on lung
 function tests. In contrast to asthma, this limitation is poorly reversible and usually gets
 increasingly worse over time.

 The COPD registry is a non-interventional multicentre observational prospective database
 focusing on the collection and analysis of data on real mortality and morbidity in COPD
 population of the Czech Republic population of COPD patients. Monitoring is done at the
 occasion of regular check-ups, followed by retrospective search of data in the documentation,
 and a record into the registry.

 The aim of Czech National Research Database of Chronic Obstructive Pulmonary Disease is to
 establish the clinical course of severe forms of COPD, establish the cause for deterioration
 of clinical status of our patients and describe the progression of COPD to death.

 The registry fulfils general objectives of health registries such as monitoring of causes,
 development, treatment and consequences of a severe disorder, including economic and social
 impacts. Statistical and scientific analyses of the registry data are focused, in particular,
 on the assessment of health determiners of the selected patient cohort with the aim to
 improve health status of the patients.
Chronic Obstructive Pulmonary Disease (COPD) is a treatable and preventable clinically
 heterogeneous syndrome with dominant respiratory symptoms and various systemic consequences.
 The incidence of COPD is increasing worldwide. In general, COPD is caused by a prolonged
 inflammatory reaction of a genetically predisposed individual exposed to long-term inhalation
 of air pollution, harmful particles and gases. This disease has a negative progression in
 time even after end of exposure. The pulmonary component is associated with expiratory
 airflow limitation, which is not fully reversible. The airflow limitation in COPD develops
 gradually as a result of chronic, primarily non-infectious inflammation of the airways and
 lung parenchyma. Systemic consequences are often found in cardiovascular, musculoskeletal and
 other systems. COPD can be considered a proven pre-cancerous condition.

 Up-to-date and precise clinical and epidemiological data describing the situation in the
 Czech Republic is currently unavailable. The Czech Republic still does not have any data on
 representation of different phenotypes among COPD patients.

 The COPD Register is a non-interventional multicenter observational prospective database
 focusing on the collection and analysis of data on real mortality and morbidity in an
 unselected (consecutive) population of patients with severe forms of COPD
 (post-bronchodilator FEV1≤ 60%). Monitoring is done at the occasion of regular check-ups,
 followed by retrospective search of data in the documentation, and a record into the registry
 subsequently.

 The main purposes of this study:

 -  Assessment of all-cause mortality

 -  Assessment of morbidity:

 (A) acute exacerbation of COPD (B) acute non-COPD respiratory events (C) acute
 non-respiratory events (D) cancers (E) ischemic heart disease (infarct, angina pectoris,
 congestive heart failure and arrhythmia)

 Other aims of this study:

 -  Monitoring of lung function decline (post-bronchodilator FEV1)

 -  Monitoring of prognostic indices

 -  COPD categories and quality of life

 -  Evaluation of activity of daily living

 -  Assessment of therapeutic compliance

 -  Note: MMAS-4 questionnaire by Prof. Donald E. Morisky will not be used as of
 September 2018

 -  Analysis of extra-pulmonary impairment during
Inclusion Criteria:

 -  Post-bronchodilator FEV1/VC < LLN and post-bronchodilator FEV1 ≤ 60% of the predicted
 value (VC - Vital Capacity, LLN - Lower Limit of Normal)

 -  Definite clinical diagnosis of COPD (can be overlaps: COPD + asthma / COPD +
 bronchiectasis)

 -  Stable course of COPD (≥ 8 weeks free of acute exacerbations and/or free of any acute
 conditions)

 -  Informed consent

 Exclusion Criteria:

 -  "Pure" bronchial asthma without COPD

 -  "Pure" bronchiectasis without COPD

 -  Cystic fibrosis

 -  End-stage of COPD

 -  Non-curable malignancy

 -  Total non-compliance

 -  Immobility